Weil's Appellate & Strategic Counseling group welcomes you to Weil's SCOTUS Term Review. Here, we summarize and analyze the cases from the 2023 Supreme Court Term that are most germane to our clients' businesses.
Filed under:
USA, Arbitration & ADR, Capital Markets, Corporate Finance/M&A, Healthcare & Life Sciences, Insolvency & Restructuring, Litigation, Media & Entertainment, Weil Gotshal & Manges LLP, US Securities and Exchange Commission, US Food and Drug Administration, Federal Trade Commission (USA), Consumer Financial Protection Bureau (USA), Dodd-Frank Wall Street Reform and Consumer Protection Act 2010 (USA), False Claims Act 1863 (USA), Americans with Disabilities Act 1990 (USA), Administrative Procedure Act, Federal Arbitration Act 1926 (USA), Supreme Court of the United States, Financial services banks, Financial services corporate, Hardware, devices & electronic equipment, Media, Software & SAAS, Technology
Location:
On December 20, 2022, the Office of Science and Technology Policy (OSTP) issued a notice of request for information (RFI) on the regulation of biotechnology on behalf of the U.S. Food and Drug Administration (FDA), the U.S. Environmental Protection Agency (EPA), and the U.S. Department of Agriculture (USDA).
Filed under:
Authors:
Location:
Firm: